Eli Lilly and Company (LLY)
-NYSE 52.36 
0.31(0.60%) 18 Jun 04:01 SGT|After Hours
:
52.36 0.00 (0.00%) 18 Jun 04:42 SGT
| Prev Close: | 52.05 |
|---|
| Open: | 52.45 |
|---|
| Bid: | 52.07 x 200 |
|---|
| Ask: | 52.55 x 200 |
|---|
| 1y Target Est: | 56.47 |
|---|
| Beta: | 0.35 |
|---|
| Next Earnings Date: | 24-Jul-13 |
|---|
| Day's Range: | 52.20 - 53.05 |
|---|
| 52wk Range: | 41.41 - 58.40 |
|---|
| Volume: | 5,135,100 |
|---|
| Avg Vol (3m): | 4,962,580 |
|---|
| Market Cap: | 56.76B |
|---|
| P/E (ttm): | 12.58 |
|---|
| EPS (ttm): | 4.16 |
|---|
| Div & Yield: | 1.96 (3.80%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Lilly to take over development of diabetes drugAP(Tue, 01:20 SGT)
- Lilly stops mid-stage Alzheimer's drug studyAP(Fri, 14 Jun)
- Sanofi steps up diabetes drive as rivals raise the stakesReuters(Fri, 7 Jun)
- Perrigo seeks approval of generic AxironAP(Wed, 29 May)
- Sector Snap: Analysts expect pharma restructuringAP(Tue, 28 May)
- Veeva Systems planning initial public offering: sourcesReuters(Wed, 1 May)
- Drugmaker Eli Lilly to cut 1,000 U.S. sales jobs -sourceReuters(Fri, 12 Apr)
- U.S. struggles with pharmaceutical goals in Asia trade talksReuters(Fri, 29 Mar)
- U.S. struggles with pharmaceutical goals in Asia trade talksReuters(Fri, 29 Mar)
- Mylan, Biocon help market generic insulin drugsAP(Thu, 14 Feb)
Key Statistics
| Forward P/E (1 yr): | 19.11 |
|---|
| P/S (ttm): | 2.50 |
|---|
| Ex-Dividend Date: | 14-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.93 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.00 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | -5.68 |
|---|
Business Summary
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The companys neuroscience products treat major depressive disorders; schizophrenia, acute mixed or manic episodes associated with bipolar I...
View More